Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eye Care Benefits of Anti-Aging Compound Capsules in Healthy Adults (Eye Care)

14. Juni 2026 aktualisiert von: Hui Wen Lin, China Medical University Hospital

Exploring the Eye Care Benefits of Anti-aging Compound Capsules

This study aims to evaluate the eye care benefits of anti-aging compound capsules in healthy adults. Participants will consume anti-aging compound capsules containing botanical extracts, omega-3 fatty acids, vitamins, minerals, and hyaluronic acid for four weeks.

The primary outcome is the improvement of ocular discomfort and eye fatigue symptoms assessed using the Ocular Surface Disease Index (OSDI). Secondary outcomes include visual acuity, accommodative function, tear film stability, macular pigment optical density, intraocular pressure, and photostress recovery time. The study will investigate whether daily supplementation with anti-aging compound capsules can improve visual comfort and support ocular health.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Visual fatigue and ocular discomfort have become increasingly prevalent due to prolonged use of digital devices, environmental stressors, and age-related changes in visual function. Nutritional supplementation containing antioxidants, carotenoids, omega-3 fatty acids, vitamins, minerals, and other bioactive compounds may help maintain ocular health and visual performance.

This prospective, single-arm, open-label clinical study aims to evaluate the eye care benefits of anti-aging compound capsules in healthy adults. Twenty-five participants will be enrolled and instructed to consume anti-aging compound capsules for four consecutive weeks.

Each capsule contains 550 mg of a proprietary formulation consisting of grape skin extract, marigold flower extract, red algae extract, fish oil, black soybean seed coat extract, Streptococcus fermentation products containing sodium hyaluronate, black pepper extract, zinc glycinate, selenium yeast, vitamins A, B1, B2, B6, B12, niacin, vitamin E, soybean lecithin, and glycerol fatty acid esters.

Participants will consume two capsules twice daily for a total daily intake of 2,200 mg. Ophthalmic assessments will be performed at baseline, Week 2, and Week 4.

The primary outcome measure is the Ocular Surface Disease Index (OSDI) score. Secondary outcome measures include distance visual acuity, near visual acuity, accommodative response, accommodative facility, tear film break-up time, macular pigment optical density, intraocular pressure, and photostress recovery time.

The study aims to determine whether supplementation with anti-aging compound capsules can improve eye fatigue symptoms and support ocular health in healthy adults.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

25

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Taiwan
      • Taichung, Taiwan
        • Department of Optometry, Chung Shan Medical University

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene

Akzeptiert gesunde Freiwillige

Ja

Beschreibung

Inclusion Criteria:

  • Adults aged 20 to 60 years. Willing to participate in the study and able to provide written informed consent.

Spherical equivalent refractive error less than 700 diopters of myopia (i.e., < -7.00 D).

Exclusion Criteria:

  • Regular consumption within the past 1 month of dietary supplements primarily indicated for eye health, or products containing active ocular health-related ingredients that may influence study outcomes (e.g., high-dose lutein ≥10 mg/day or zeaxanthin ≥2 mg/day). Use of general multivitamins or non-eye-specific supplements containing low-dose related ingredients (≤2 mg) may be allowed at the discretion of the investigators.

History of ocular infection or ocular surgery within the past 3 months. Clinically diagnosed ocular diseases, including but not limited to glaucoma, cataract, age-related macular degeneration, or diabetic retinopathy, or a history of ocular procedures such as cataract surgery, retinal laser therapy, or refractive surgery (e.g., LASIK).

Known or self-reported hypersensitivity or allergic reaction to any component of the investigational product, including but not limited to fish oil, soybean-derived products, gelatin (bovine source), yeast, or any other listed ingredients.

Individuals with direct affiliation, supervisory, evaluative, or dependent relationships with the research team, including but not limited to:

Students taught, supervised, or evaluated by members of the research team; Laboratory or research assistants, staff, or collaborators within the same research unit; Interns, part-time workers, or employees under the supervision of the research team.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Unterstützende Pflege
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Anti-Aging Compound Capsules
Participants will receive anti-aging compound capsules containing botanical extracts, omega-3 fatty acids, vitamins, minerals, and hyaluronic acid for 4 weeks. Participants will take 2 capsules twice daily (total daily dose 2,200 mg).
Nahrungsergänzungsmittel: Anti-Aging Compound Capsules
Participants will consume anti-aging compound capsules twice daily for 4 weeks. Each capsule contains 550 mg of a proprietary formulation consisting of grape skin extract, marigold flower extract, red algae extract, fish oil, black soybean seed coat extract, Streptococcus fermentation products containing sodium hyaluronate, black pepper extract, zinc glycinate, selenium yeast, vitamins A, B1, B2, B6, B12, niacin, vitamin E, soybean lecithin, and glycerol fatty acid esters. Total daily intake is 2,200 mg.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Ocular Surface Disease Index (OSDI) Score
Zeitfenster: baseline / week2 / week4
Changes in ocular discomfort and eye fatigue symptoms will be assessed using the Ocular Surface Disease Index (OSDI) questionnaire. The OSDI is a validated 12-item questionnaire used to evaluate symptoms related to ocular surface disease and visual function. Assessments will be performed at baseline, Week 2, and Week 4. A decrease in OSDI score indicates improvement in ocular symptoms.
baseline / week2 / week4
Change in Distance Visual Acuity (DVA, logMAR)
Zeitfenster: baseline / week2 / week4
Changes in distance visual acuity will be measured using a Snellen chart at 6 meters and converted to logarithm of the minimum angle of resolution (logMAR) for statistical analysis. Assessments will be performed at baseline, Week 2, and Week 4.
baseline / week2 / week4
Change in Near Visual Acuity (NVA)
Zeitfenster: baseline / week2 / week4
Changes in near visual acuity will be assessed using a Snellen near-vision chart at a distance of 40 cm. Assessments will be performed at baseline, Week 2, and Week 4.
baseline / week2 / week4
Change in Accommodative Response
Zeitfenster: baseline / week2 / week4
Accommodative response will be measured using a Shin-Nippon NVision-K5001 open-field autorefractor, including accommodative lag and accommodative lead. Measurements will be conducted at baseline, Week 2, and Week 4.
baseline / week2 / week4
Change in Accommodative Facility (cycles per minute)
Zeitfenster: baseline / week2 / week4
Accommodative facility will be assessed using ±0.50 diopter flipper lenses with standard accommodative targets. Results will be recorded as cycles per minute (CPM). Assessments will be performed at baseline, Week 2, and Week 4.
baseline / week2 / week4
Change in Tear Film Break-Up Time (TBUT)
Zeitfenster: baseline / week2 / week4
Tear film stability will be evaluated using non-invasive tear break-up time measured by a corneal topography system (Topcon CA-800). Assessments will be conducted at baseline, Week 2, and Week 4.
baseline / week2 / week4
Change in Macular Pigment Optical Density (MPOD)
Zeitfenster: baseline / week2 / week4
Macular pigment optical density will be measured using a macular pigment optical density analyzer. Assessments will be performed at baseline, Week 2, and Week 4.
baseline / week2 / week4
Change in Photostress Recovery Time
Zeitfenster: baseline / week2 / week4
Photostress recovery time will be assessed by measuring the time required for visual function to return to baseline following exposure to a standardized bright light stimulus. Assessments will be performed at baseline, Week 2, and Week 4.
baseline / week2 / week4

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Intraocular Pressure (IOP)
Zeitfenster: baseline / week2 / week4
Intraocular pressure will be measured using non-contact tonometry. Measurements will be performed at baseline, Week 2, and Week 4.
baseline / week2 / week4

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

China Medical University Hospital

Ermittler

  • Hauptermittler: Lin, associated professor, Institute of Medical Research, Chung Shan Medical University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

30. April 2026

Primärer Abschluss (Tatsächlich)

3. Juni 2026

Studienabschluss (Tatsächlich)

10. Juni 2026

Studienanmeldedaten

Zuerst eingereicht

14. Juni 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

14. Juni 2026

Zuerst gepostet (Tatsächlich)

18. Juni 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. Juni 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

14. Juni 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • CS1-25234

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data (IPD) will not be shared due to ethical and privacy considerations. The dataset includes ophthalmic measurements and health-related questionnaire data that could potentially identify participants. Data may be available upon reasonable request and with approval from the corresponding ethics committee.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Augenermüdung

Klinische Studien zur Anti-Aging Compound Capsules

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Ukraine

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren